Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
toripalimab + nab-paclitaxel + cisplatin
- Development stage
- Unknown
- Lead developer
- Junshi Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
A combination immunotherapy-chemotherapy regimen consisting of toripalimab (a PD-1 inhibitor), nab-paclitaxel (albumin-bound paclitaxel, a taxane chemotherapy), and cisplatin (a platinum-based chemotherapy). This regimen works through multiple mechanisms: toripalimab blocks the PD-1 pathway allowing T-cells to remain active against cancer cells, nab-paclitaxel disrupts microtubule function essential for cell division, and cisplatin crosslinks DNA preventing replication and transcription.
- Brand names
- TuoyiLoqtorziAbraxanePlatinol
- Other names
- JS001 + Nab-Paclitaxel + CisplatinToripalimab plus Nab-Paclitaxel with or without CisplatinToripalimab + Nab-Paclitaxel + Cisplatin
02
Targets
DNAMicrotubulePDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on toripalimab + nab-paclitaxel + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on toripalimab + nab-paclitaxel + cisplatin.